Height reduction in 539 tall girls treated with three different dosages of ethinyloestradiol

E K Normann, O Trygstad, S Larsen, K Dahl-Jørgensen

Abstract
During the period 1970 to 1985, 539 constitutionally tall girls were treated with ethinyloestradiol in varying dosages to reduce final height. They all had a predicted final height above 181 cm (>+2·5 SD). The girls were all healthy and were treated with three different dosages of ethinyloestradiol. Throughout these 15 years recommended treatment regimens changed, and the treatments described followed these guidelines. Girls in group 1 (n=263) were treated with 0·5 mg of ethinyloestradiol, group 2 (n=178) with 0·25 mg, and group 3 (n=98) with 0·1 mg. The total mean (SEM) reduction of final height was 5·9 (0·2), 5·3 (0·1), and 4·4 (0·2) cm when treated with 0·5, 0·25, and 0·1 mg respectively. Group 1 was treated for 2·02 (0·03) years and group 2 and 3 for 1·85 (0·04) and 1·63 (0·05) years respectively. When expressed in relation to the treatment period the reduction of final height was 3·0 (0·1), 3·1 (0·1), and 2·9 (0·2) cm/year of treatment respectively. All the girls were treated with ethinyloestradiol as a daily single dose, while progestogen was given daily the first 10 days of every month.

In conclusion we found that a daily dose of ethinyloestradiol 0·1 mg for about 20 months is sufficient to reduce final height. We recommend starting treatment at a bone age of about 12 years.

Tall stature is usually defined as body height of >+2 SD above the population mean.1 In Norway the average final height is 167·3 cm in girls. According to this definition, tall stature in Norway is final height above 178·3 (SD 5·5) cm.2 In 1956 Goldzieher introduced oestrogen as treatment of excessive growth in adolescent girls.3 Since then there have been several different regimens for treating tall girls. Many investigators used conjugated oestrogens, and others used ethinyloestradiol, in varying dosages, usually combined with a progestogen 7–10 days each month to give regular vaginal bleedings. In the 1960s most practitioners used 0·5 mg of ethinyloestradiol, 0·25–0·30 mg in the 1970s, and in the 1980s there have been reports indicating that 0·1 mg is sufficient.1 4–14 However, these studies include a relatively small number of patients (n=5–100).

Arterial thromboembolic complications and possible carcinogenic effects of the long-term oestrogen treatment by contraceptive pills make it important to find the lowest dosage of oestrogen giving a satisfactory reduction of final height. We have compared the growth reducing effect of three different dosages in 539 tall girls, demonstrating that low dose (0·1 mg) treatment is as effective as high dose (0·5 mg). Furthermore, we have studied the optimum age for start of treatment in relation to the treatment period needed.

Patients and methods
PAtients
During the period 1970 to 1985, 1143 girls were evaluated at the outpatient clinic of the Department of Paediatrics, The National Hospital (Oslo, Norway), because of tall stature. They all went through a full physical examination. Only girls with a predicted height above >+2·5 SD of the normal Norwegian population, corresponding 181 cm, were offered treatment. There were 539 of these girls; all accepted treatment and were enrolled in this study. The other girls were not followed up.

METHODS
Standing height was measured by a Holtain stadiometer and the bone age was estimated from a hand x ray film according to the Greulich-Pyle radiographic atlas.13 To reduce variation the bone age was determined by one of the authors only (OT) and one experienced paediatric radiologist. If their estimates differed by more than six months the x ray film was re-examined to reach agreement. The final height was predicted from the estimated bone age, according to the Bayley-Pinneau tables.16 The x ray film of 11 year old girls in the radiographic atlas of Greulich-Pyle caused problems because it is more mature than the picture of 12 year old girls. To get the correct bone age it was necessary to use the film of 13–13·5 year old boys instead (156 months of age) which corresponded to 11 year old girls (132 months of age).17 Concentrations of growth hormone, prolactin, oestrogen, progesterone, follicle stimulating hormone, and luteinising hormone and activities of aspartate aminotransferase and alanine aminotransferase were measured and found normal.

The 539 girls were all treated with ethinyloestradiol (Etfollin, Nycomed). In the late 1960s and the 1970s, 0·5 mg of ethinyloestradiol was used as a single dose combined with norethisterone 10 mg daily the first 10 days of every month (group 1, n=263). In 1981 ethinyloestradiol was reduced to 0·25 mg daily and norethisterone reduced to 5 mg the first 10 days of every month (group 2, n=178). In 1982 norethisterone was replaced with medroxypro-
gesteroneacetate (MPA) 5 mg (Perlutex, Leo)
because of the androgenic effect of norethisterone as hirsutism.\textsuperscript{13} In 1983 ethinylestradiol was further reduced to 0.1 mg daily combined with 5 mg of MPA the first 10 days of every month (group 3, n=58). The girls in group 1 received a total dose of 396 mg, group 2, 169 mg, and group 3, 60 mg of ethinylestradiol.

The girls were seen every fourth month at the outpatient clinic. They were measured, pubertal development stage was registered, and side effects noted. The bone age was estimated at six month intervals. Treatment was ended when the predicted final height was reduced to less than 180 cm, meaning that they would not become taller than about 180 cm after termination of treatment. They were followed up regularly until growth had stopped.

STATISTICAL METHODS
All results are expressed as mean values with either 95% confidence interval or SEM. The confidence intervals were calculated by using Student’s procedure.\textsuperscript{16} All tests were carried out two tailed and the differences considered significant when the p values were less than or equal to 5%. The groups were compared by two way layout analysis of variance.\textsuperscript{19}

Table 1 Data from a study of 539 girls treated with three different dosages of ethinylestradiol (95% confidence interval)

<table>
<thead>
<tr>
<th>No of patients</th>
<th>Group 1 (0.5 mg)</th>
<th>Group 2 (0.25 mg)</th>
<th>Group 3 (0.1 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>263</td>
<td>178</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>Chronological age (years)</td>
<td>13-2 (13-0 to 14-4)</td>
<td>13-1 (12-9 to 13-3)</td>
<td>13-8 (13-6 to 14-0)</td>
</tr>
<tr>
<td>Bone age (years)</td>
<td>12-6 (12-5 to 12-7)</td>
<td>12-6 (12-5 to 12-7)</td>
<td>12-7 (12-6 to 12-8)</td>
</tr>
<tr>
<td>Height at start of treatment (cm)</td>
<td>175-0 (174-4 to 175-6)</td>
<td>175-4 (174-8 to 176-0)</td>
<td>174-2 (173-6 to 174-8)</td>
</tr>
<tr>
<td>Predicted height (cm)</td>
<td>185-1 (184-7 to 185-5)</td>
<td>185-5 (185-1 to 185-9)</td>
<td>183-1 (182-7 to 183-5)</td>
</tr>
<tr>
<td>Final height (cm)</td>
<td>179-2 (178-8 to 179-6)</td>
<td>180-2 (179-8 to 180-6)</td>
<td>178-7 (178-3 to 179-1)</td>
</tr>
<tr>
<td>Reduction of final height (cm)</td>
<td>5-9 (5-5 to 6-3)</td>
<td>5-3 (5-1 to 5-5)</td>
<td>4-4 (4-0 to 4-8)</td>
</tr>
<tr>
<td>Treatment period (years)</td>
<td>2-02 (2-00 to 2-08)</td>
<td>1-85 (1-77 to 1-93)</td>
<td>1-63 (1-53 to 1-73)</td>
</tr>
<tr>
<td>'Corrected' reduction (cm/year of treatment)</td>
<td>3-0 (2-8 to 3-2)</td>
<td>3-1 (2-9 to 3-3)</td>
<td>2-9 (2-5 to 3-3)</td>
</tr>
<tr>
<td>'Relative' reduction (mm/mg ethinylestradiol given)</td>
<td>0-16</td>
<td>0-31</td>
<td>0-73</td>
</tr>
</tbody>
</table>

Table 2 Data of 539 girls treated with ethinylestradiol, divided according to bone age (95% confidence interval)

<table>
<thead>
<tr>
<th>Bone age (years)</th>
<th>&lt;12-5</th>
<th>12-5-13-0</th>
<th>&gt;=13-0</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of girls</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronological age (years)</td>
<td>13-0 (12-9 to 13-1)</td>
<td>13-1 (13-0 to 13-2)</td>
<td>13-2 (13-1 to 13-3)</td>
</tr>
<tr>
<td>Height at start of treatment (cm)</td>
<td>174-1 (173-6 to 174-5)</td>
<td>175-0 (174-9 to 175-2)</td>
<td>175-5 (174-9 to 176-1)</td>
</tr>
<tr>
<td>Predicted height (cm)</td>
<td>185-5 (185-0 to 186-0)</td>
<td>185-7 (185-2 to 186-4)</td>
<td>185-5 (184-9 to 186-1)</td>
</tr>
<tr>
<td>Final height (cm)</td>
<td>178-9 (178-4 to 179-3)</td>
<td>179-7 (179-2 to 180-1)</td>
<td>179-5 (178-9 to 180-1)</td>
</tr>
<tr>
<td>Reduction of final height (cm)</td>
<td>6-3 (5-8 to 6-9)</td>
<td>5-9 (5-4 to 6-5)</td>
<td>5-4 (5-0 to 5-9)</td>
</tr>
<tr>
<td>Treatment period (years)</td>
<td>3-1 (2-8 to 3-5)</td>
<td>3-2 (2-9 to 3-4)</td>
<td>3-1 (2-8 to 3-4)</td>
</tr>
<tr>
<td>'Corrected' reduction (cm/year)</td>
<td>3-3 (3-0 to 3-6)</td>
<td>3-1 (2-8 to 3-4)</td>
<td>3-0 (2-7 to 3-3)</td>
</tr>
<tr>
<td>'Corrected' reduction (mm/mg ethinylestradiol given)</td>
<td>0-07</td>
<td>0-05</td>
<td>0-06</td>
</tr>
</tbody>
</table>

Results
The auxological data at start of treatment showed no difference in chronological age, bone age, or height at start of treatment between the three groups (table 1). The predicted heights, final heights, and the reductions of final height in the three groups are shown in table 1.

The differences between the groups in reduction of final height was significant (p<0.001). The duration of treatment was different in the three groups. When related to the different duration of treatment periods the height reduction was no longer significantly different between dosage regimens.

The groups were subdivided in relation to the bone age (table 2): <12-5 years, 12-5-13-0, and >=13-0 years. This gave us an opportunity to compare the effects of different dosages of ethinylestradiol according to the bone age at onset of treatment. Because of the difference in treatment period between the groups it was necessary to compare the growth inhibiting effect after correction for the duration of treatment. For bone age <12-5 years the difference in reduction of final height between the three dosage regimens was significant (p<0.001). The difference between the groups in 'corrected' height reduction (cm/year of treatment) was not significant.
In the group with bone age 12.5–13.0 years the height reduction was significantly different between the three dosage regimens (p<0.01), but there was no significant difference between the groups in ‘corrected’ reduction.

In the most mature group (bone age ≥13.0) there was no significant difference between the three dosage regimens in either total or ‘corrected’ height reduction (fig 1).

In none of these groups did the girls develop side effects that lasted more than three months. The main side effect was nausea. Some had dysmenorrhoea, but usually this disappeared after some months. A detailed report on side effects was published earlier and showed fewer problems with low dose treatment.13 The girls were not followed up systematically after completion of treatment. Some have become mothers and, as far as we know, none has developed infertility problems or malignant disease. This is too early to ascertain breast and genital carcinomas. No girl has developed pro-lactinoma to our knowledge.

Discussion
In 1975 Zachmann et al reported a study of 40 girls treated with a daily dosage of 0.3 mg of ethinyloestradiol.20 The average reduction of final height was 4.6 cm. The reduction in the youngest group with bone age 12.1–13 years was 5.8 cm while the reduction in the group with bone age 13.1–14 years was 4.0 cm. The group with bone age 14.1–15 had a reduction of 4.5 cm. The differences were not significant, but they gave an indication that the reduction of final height was less when treatment was started after bone age of about 13 years. This corresponded to the study of Kuhn et al reported in 1977.21 They presented a study with 17 girls treated with 0.5 mg daily of ethinyloestradiol. The reduction of final height was significantly greater when treatment was started before a bone age of 12 years. The mean reduction was 8.9 cm when bone age was less than 12 years and 5.5 cm when between 12 and 13 years. There was not a statistical difference in reduction before compared with after menarche (6.4 v 5.7 cm respectively). In 1978 Bierich reported a study of 41 girls treated with 7.5 mg of conjugated oestrogen daily.20 The average height reduction was 7.3 cm, but 8.3 cm when treated before menarche (mean bone age 11.8 years) and 6.8 cm when treated after menarche (mean bone age 12.9 years).

Also in 1978 Crawford reviewed different oestrogen regimens. They all showed height reductions between 3.5 and 7.3 cm. However, he did not discuss whether high or low dose regimens gave different results. In 1989 Grüters et al reported one of the first studies where the reduction of final height in different dosage regimens was compared. They showed that the reduction of final height was 4.9 cm in the low dose (0.1 mg of ethinyloestradiol daily) compared with 5.1 cm in the high dose (0.3–0.5 mg daily) regimen. This difference was not significant. The final height was reduced when treatment was started at a bone age less than 13 years. The groups were small (n=44 and n=38 respectively) and they were treated at two different centres.

These results are all in accordance with ours. There is no statistical difference in growth inhibiting effect between the three dosages when the duration of treatment and bone age at start of treatment are taken into account. Using 0.1 mg of ethinyloestradiol is as efficient as 0.5 mg. It has been suggested that in girls with more advanced pubertal development, a higher dosage of oestrogen should be more effective.15 In girls with bone age ≥13.0 years the total height reduction was 6 mm less when given 0.1 mg daily compared with the 0.5 mg regimen, but when correlated to the treatment period there was no difference. This does not justify a higher dosage (0.5 mg) which would, with a treatment period of 2.02 years, be equivalent to a total dose of about 36 years’ use of a low dose (35 µg) contraceptive pill compared with six years when treated with 0.1 mg ethinyloestradiol daily for 1.63 years. Thus irrespective of the bone age when starting treatment, low dose oestrogen treatment is as effective as high dose treatment. Furthermore early treatment, starting before bone age 12.5 years, is most effective. After bone age 13 years less benefit is obtained. There is a definite decrease in growth reducing effect when bone age is ≥13.0 years. The difference in reduction of final height between the two groups with bone age less than 13 years is clinically not significant, although it is statistically different due to the large number of patients.

This is the first report including more than 500 tall girls from only one centre examined and treated by the same investigator. This minimises the variations observed in height measurements, bone age estimations, height predictions, and indications of treatment.

From our study we conclude that starting treatment at a bone age of about 12.0–12.5 years, using 0.1 mg of ethinyloestradiol daily for about two years, combined with 5 mg medroxyprogesteroneacetate daily for the first 10 days of every month, will give satisfactory results with an average reduction of final height of 5.2 cm. Because of the possibility of nausea, with or without vomiting, we recommend starting treatment on a Friday to minimise loss of schooling. Such side effects are most frequent with higher
dosages. As Trygstad reported in 1986, there has not been a problem of major side effects. Whether even lower dosages (for example 35 µg daily) are equally effective should be assessed in a prospective clinical trial.